Troponin POCT in the Diagnosis of an Acute Myocardial Infarction

Sponsor
Ziekenhuis Oost-Limburg (Other)
Overall Status
Completed
CT.gov ID
NCT03400553
Collaborator
(none)
71
1
1
24.4
2.9

Study Details

Study Description

Brief Summary

Thoracic pain can be caused by a life threatening disease as for instance a heart attack. Fast diagnosis and treatment is necessary for an advantageous clinical outcome. When a patient enters the emergency unit, an electrocardiogram (ECG) can diagnose a heart attack by recording the electrical activity of the patients' heart. However, an increasing number of patients with an acute myocardial infarction (AMI) are presenting without significant abnormalities on ECG In the latter group, diagnosis is dependent of elevated biochemical markers of myocardiocyte necrosis in the blood such as troponin. Generally, troponins are determined in blood and are analyzed by radiometry or at the hospital's laboratory. Time loss in the acquisition of troponin levels can occur during the workflow due to blood sampling difficulties, transport of the blood samples, processing in the laboratory, and processes inherent to the measuring assays. Roche developed a portable point-of-care (POC) device that determines troponin-T in a few minutes by using small volumes of the patient's blood with the added value that this device can be used in a pre-hospital setting which might save a significant amount of time in determining troponin levels.In this way, a faster diagnosis of AMI can be made improving patients' outcome.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Blood analysis
N/A

Detailed Description

In this prospective pilot study, 70 patients will be recruited over a time period of one year, with non-traumatic thoracic pain in a pre-hospital setting. While the ambulance or MUG is transporting such a patient, he/she is asked (informed consent) if an extra blood sample can be taken for measuring troponin levels by the portable device of Roche (cobas h232®). This can be done during the same venipuncture needed for standard-of-care analysis of the two other blood samples used for troponin-T by the radiometer and the laboratory. An ECG is performed in the ambulance and when it is positive, a patient is diagnosed immediately with acute myocardial infarction (AMI) and will be to transported as fast as possible to the coronary care unit. The blood samples retrieved in the ambulance are transported to the lab and to the table top radiometer in the emergency unit. As stated before, an increasing number of patients with AMI are presenting without significant abnormalities on ECG. Therefore, the troponin-T levels in the blood sample will provide extra information to make an appropriate diagnosis. It is our hypothesis, that the Cobas h232 device will provide faster results and thus a faster diagnosis of AMI which benefit patients' outcome.

Study Design

Study Type:
Interventional
Actual Enrollment :
71 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Time Gain of Pre-hospital Troponin Point of Care Testing in the Diagnosis of an Acute Myocardial Infarction
Actual Study Start Date :
Jan 1, 2018
Actual Primary Completion Date :
Dec 13, 2019
Actual Study Completion Date :
Jan 15, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: non-traumatic thoracic pain

Patients with out-of-hospital non-traumatic thoracic pain admitted to the emergency unit via ambulance or MUG will be screened for enrolment. Blood analysis for troponin-T will be performed by 3 different devices as explained earlier.

Diagnostic Test: Blood analysis
The blood of the patients will be analyzed for troponin T measured with 3 different devices: 1) a point-of-care (POC) test performed in the ambulance or MUG, a handheld cobas h232 POC system® (Roche Diagnostics, Switzerland), 2) a POC test at the emergency room, a table top AQT90 FLEX® (Radiometer, The Netherlands) and 3) a central laboratory test performed on cobas® 8000 (Roche Diagnostics, Switzerland).

Outcome Measures

Primary Outcome Measures

  1. The time to diagnosis of acute myocardial infarction (AMI) [one hour]

    The time between blood sample and the result of each device will be compared against the other devices. According to the troponin level, the diagnosis will be made. Troponin T< 5 ng/L: negative for AMI; Troponin-T>50 ng/L: positive for AMI; Troponin-T: 5-50 ng/L: observation and a second blood sample has to be taken for re-evaluation of troponin-T.

Secondary Outcome Measures

  1. Time since onset of chest pain to first blood sample [one hour]

    The time since onset of chest pain will be asked to the patient. The faster a patient will call to the emergency unit, the better the outcome.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Non-traumatic thoracic pain

  • Transportation via ambulance or MUG

  • Written informed consent form (ICF) has to be obtained from the patient

Exclusion Criteria:
  • Age <18 years

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ziekenhuis Oost-Limburg Genk Belgium 3600

Sponsors and Collaborators

  • Ziekenhuis Oost-Limburg

Investigators

  • Principal Investigator: Pascal Vanelderen, MD PhD, Ziekenhuis Oost-Limburg

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ziekenhuis Oost-Limburg
ClinicalTrials.gov Identifier:
NCT03400553
Other Study ID Numbers:
  • Troponin-T POCT
First Posted:
Jan 17, 2018
Last Update Posted:
Jan 22, 2020
Last Verified:
Jan 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 22, 2020